Cleveland PR Newswire

Press releases from Ohio companies

Prasco Enters into Agreements with sanofi-aventis U.S. to Provide Sales Support and Distribution Services for Authorized Generic Versions Under the Winthrop Label in U.S.

  - ALLEGRA-D® 12 HOUR (fexofenadine HCl 60 mg and pseudoephedrine HCl 120
   mg) Extended-Release Tablets and Drisdol (ergocalciferol) Capsules now
   available as authorized generics under the Winthrop label in the U.S.

    CINCINNATI, Nov. 2 /PRNewswire/ -- Prasco Laboratories announced today
that it has entered into agreements with Winthrop U.S., a business of
sanofi-aventis U.S., to provide sales support and distribution services to
Winthrop U.S. for authorized generic versions of Allegra-D® 12 Hour
(fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) extended-release
tablets and Drisdol® (ergocalciferol) capsules in the United States under
the Winthrop label. Fexofenadine HCl and pseudoephredrine HCl
extended-release tablets and ergocalciferol capsules represent the first
two products launched in the U.S. by Winthrop U.S. under the Winthrop label
with Prasco providing sales support and distribution services to Winthrop
U.S. Prasco expects to begin shipping the products immediately. Specific
financial terms of the agreements were not disclosed.

    "We are especially proud to expand our relationship with sanofi-aventis
U.S., and we are certainly pleased to provide pharmacists and consumers
with these authorized generic options," said Prasco Chief Executive Officer
E. Thomas Arington. "Consumers and pharmacists can have confidence in their
prescription drug choices, when they have the identical product, quality,
reliability of supply and the identical experience that only the brand can
provide."

    ALLEGRA-D and DRISDOL are registered trademarks of sanofi-aventis.

    About Prasco

    Prasco provides patients, pharmacists and customers with generic
options that deliver the identical brand experience. The company's business
model encourages competition and benefits consumers through significant
cost savings.

    Prasco sells its product line through the major distribution channels,
including chains, independent pharmacies, distributors, wholesalers, and
managed care providers. Prasco operates from a cGMP compliant VAWD
certified 160,000 sq. ft. office and warehouse facility including
DEA-approved facilities for Schedule II-V controlled drug products. For
more information, visit http://www.prasco.com.